Deucrictibant Speeds Relief in Hereditary Angioedema Trial
A phase 3 trial found the immediate-release capsule relieved symptoms of hereditary angioedema attacks faster than placebo.
Updated on Nov. 2, 2026 in Allergies
In the RAPIDe-3 phase 3 trial of 134 patients aged 12 and older with hereditary angioedema, deucrictibant immediate-release produced a median time to symptom relief of 1.28 hours, versus more than 12 hours for placebo. The results were published in The Lancet, and the FDA is reviewing the new drug application.
Why it matters
Hereditary angioedema attacks cause swelling that can be disabling, and faster-acting oral treatments could change how patients manage episodes. If approved, deucrictibant would be the first oral bradykinin B2 receptor antagonist on the market.
In the 134-patient RAPIDe-3 phase 3 crossover trial, 9% of deucrictibant-treated attacks needed rescue medication within 24 hours versus 44% on placebo. Long-term outcomes and performance across broader patient populations have not yet been reported.
The players
Riedl
Lead researcher on the RAPIDe-3 trial, affiliated with the University of California, San Diego, who stated the drug would be the first approved oral bradykinin B2 receptor antagonist if cleared.
The details
Patients treated one attack with deucrictibant and another with placebo, and symptom relief was measured with the Patient Global Impression of Change rating within 12 hours. Six treatment-emergent adverse events related to the drug occurred within three days, with no serious or severe events and no discontinuations.
Timeline
April 23, 2027: FDA target action date for the deucrictibant immediate-release decision.
Health Landscape
The RAPIDe-3 program positions deucrictibant as a potential first oral bradykinin B2 receptor antagonist for hereditary angioedema, a field long dominated by injectable therapies. An extended-release tablet, which showed an 83% monthly attack rate reduction versus placebo, is also under investigation.
If approved, the oral capsule would give patients a treatment option that acts faster than placebo at easing attack symptoms. Patients would still need to discuss with their clinicians whether it fits their attack management plan.
The takeaway
Faster-acting oral options could reshape attack management for people with hereditary angioedema, pending regulatory review and further evidence.
What happens next
The FDA's decision on the deucrictibant immediate-release application is expected by April 23, 2027.
Further reading
Explore more on Allergies to see how immune-driven swelling conditions are managed.
Source note: This article includes information reported by Healio.
